Lindera

Lindera: A Comprehensive Encyclopedic Reference

1. Identity and Botanical Classification

Genus and Family. Lindera is a genus of flowering shrubs and trees belonging to the family Lauraceae (the laurel family). It is a core genus containing more than 100 species and is a member of the Litseeae tribe under the Lauraceae family. The genus is widely distributed in tropical, sub-alpine, and temperate regions of the Asian and American continents, with approximately 80 to 100 species.

Nomenclature and Etymology. In 1783, Carl Peter Thunberg honored Johann Linder (1676–1724), a Swedish botanist and physician, by naming the genus Lindera in honor of him. The genus encompasses both deciduous and evergreen species. Like many other Lauraceae, all parts of linderas are rich in aromatic oils.

Principal Medicinal Species. While the genus is large, several species are of primary medicinal and pharmacological significance:

• Lindera aggregata (Sims) Kosterm. — The most pharmacologically studied species; Linderae Radix (Wuyao in Chinese), the dried root of L. aggregata, is a widely used traditional Chinese medicine. Also known historically as Lindera strychnifolia.
• Lindera obtusiloba Blume — A medicinal herb traditionally used in Southeast Asian countries; indigenously, extracts of different parts of the plant have been used to improve blood circulation and treat allergy, inflammation, rheumatism, and liver diseases.
• Lindera benzoin (L.) Blume — Commonly called spicebush, common spicebush, northern spicebush, wild allspice, or Benjamin bush; it is native to eastern North America, growing in the understory in moist, rich woods.
• Lindera glauca, L. neesiana, L. chunii, L. reflexa, and others — Several species are used as traditional medicines for their therapeutic effects on whitening, hepatitis C, hepatotoxicity, anti-cancer, antibacterial, antiproliferative, endothelial dysfunction, neuroprotection, antifibrotic, and post-ischemic myocardial dysfunction.

Common Names. L. aggregata is most widely known as Wuyao (乌药) in traditional Chinese medicine (TCM). L. benzoin carries common names including spicebush, wild allspice, feverbush, and Benjamin bush. L. obtusiloba is known in Korean and Japanese traditional medicine contexts.

Natural Source and Habitat. The genus Lindera includes over 100 species and contains shrubs and evergreen or deciduous trees that are intermittently scattered in tropical, subtropical, and temperate Asia as well as the Midwest. Among them, Lindera aggregata (Sims) Kosterm. is a frequently used medicinal herb found in the south of the Yangtze River basin, China. It is mainly distributed in 18 provinces in China, including Zhejiang, Jiangxi, Hunan, Gansu, Taiwan, Yunnan, Shaanxi, Sichuan, Guizhou, Hainan, Chongqing, Guangdong, Guangxi, Henan, Hubei, Anhui, Fujian, and Jiangsu provinces. The quality produced in Tiantai, Zhejiang Province is considered the best; it is called "Tai Wuyao" and is considered the region with L. aggregata abundance.

Plant Parts Used and Common Forms. The roots and leaves of L. aggregata are the medicinal and edible parts. As an edible plant, the tender leaves are consumed as a functional tea or dietary supplement for health-promoting benefits such as anti-hepatic injury and lipid-lowering activity. It can be made into decoctions, pills, or powdered forms for external application. Recently, L. aggregata has been approved as a new food resource in China.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

Dried root tubers of L. aggregata have been widely used in Chinese herbal medicine for thousands of years to promote qi, relieve pain, warm kidney, and disperse cold. It first appeared in the Ben Cao Shi Yi (Supplements to Newly Revised Materia Medica) around 739 AD.

Its tuberous root, named "Wuyao" in TCM, is a commonly used herb in China, which can regulate "Qi" (vital energy) and relieve pain, warm the kidneys, and dissipate cold. Lindera aggregata has long been used as a regulator of "Qi" (vital energy) in China, for treating chest and abdominal pain, bladder deficiency, hernia, bladder cold, dysmenorrhea, and frequent enuresis and urination.

Linderae Radix (Wuyao in Chinese), the dried root of L. aggregata, has been documented in the Chinese Pharmacopoeia and incorporated into over 20 traditional Chinese medicine formulas for treating various ailments, including rheumatic diseases, neuralgia, and abdominal pain. Linderae Radix is included in 24 formulae in the Chinese Pharmacopoeia (2020 edition).

In line with TCM principles, L. aggregata, commonly referred to as "Wuyao," is believed to invigorate and harmonize bodily metabolism, offering effects that promote Qi, alleviate pain, warm the kidney, and dispel coldness. Characterized by its pungent flavor, mild aroma, and association with the kidney and stomach meridians, L. aggregata has been used to enhance kidney functionality.

Wuyao is classified as non-toxic (无毒) in both classical sources and the modern Chinese Pharmacopoeia. The Kai Bao Ben Cao explicitly states it is "acrid, warm, and non-toxic."

2.2 Japanese Kampo Medicine

L. strychnifolia, an evergreen, is known for the root used in Kampo medicine, and has been used as a treatment for cardiac, renal, and rheumatic diseases in Japan. It is a popular herb in East Asia and is extensively used in Japan and China.

2.3 Traditional Use in Korea and Southeast Asia

Lindera obtusiloba is a medicinal herb traditionally used in Southeast Asian countries. Indigenously, extracts of different parts of the plant have been used to improve blood circulation and treat allergy, inflammation, rheumatism, and liver diseases. L. aggregata root is part of a Korean herbal medicine formula for depression.

2.4 Native American and North American Traditional Use

Lindera benzoin was used by Native Americans for many ailments and by the Cherokee and Ojibwa for flavoring food. The bark was used to make a tea as a "blood purifier" for sweating, colds, and rheumatism. The settlers described the plant as a substitute for allspice and used the twigs in a tea for colds, worms, gas, and colic. Known also as "feverbush," the bark was once widely used as a treatment for typhoid fevers and other forms of fevers.

Throughout history, many Lindera plants have been used in traditional medicine for their healing and curing capabilities for several health-related implications, such as pain, cold, urinary tract disorders, rheumatoid arthritis, gastric ulcer, abdominal pain, cholera, and beriberi.

3. Key Constituents and Active Compounds

The phytochemical investigation of different parts of L. aggregata led to the identification of up to 349 components belonging to sesquiterpenoids, alkaloids, flavonoids, essential oils, and other compounds. Among them, sesquiterpenoids, flavonoids, and alkaloids are assessed as the representative active ingredients of L. aggregata.

Over 166 chemical components have been isolated from L. aggregata, including alkaloids, sesquiterpenoids, flavonoids, cyclopentanedione derivatives and enantiomers of ketone derivatives, disesquiterpenoid-geranylbenzofuranone conjugates, benzenoids, and benzenoid glycosides.

3.1 Sesquiterpenoids

The sesquiterpenes of L. aggregata account for more than half of such compounds in the whole genus Lindera, especially the eudesmane-, lindenane-, and germacrane-types, which were almost all found in L. aggregata.

The primary sesquiterpenoid classes and their documented activities include:

• Eudesmane-type sesquiterpenes: Eudesmanes exhibit liver protection, anti-cancer, anti-fibrotic, and anti-inflammatory properties.
• Lindenane-type sesquiterpenes: Lindenanes exhibit anti-inflammatory properties and anti-oxidant activity.
• Germacrane-type sesquiterpenes: Germacranes exhibit liver protection activity.
• Isolinderalactone (ILL): A particularly important elemane-type sesquiterpene lactone. In elemanes, the representative compound isolinderalactone has significant anti-tumor activity. Isolinderalactone is a sesquiterpene isolated from root extracts of Lindera aggregata.
• Linderanoids: Novel dimeric sesquiterpene structures unique to this species.

3.2 Alkaloids

The alkaloid fraction of Radix Linderae, considered the main active component of this herb drug, has been proven to exhibit anti-inflammatory, analgesic, and antimicrobial activities.

Key alkaloids include:

• Norisoboldine (NOR): Norisoboldine is the main isoquinoline alkaloid constituent in the dry roots of Lindera aggregata. It is one of only two compounds designated as chemical markers for quality control in the China Pharmacopoeia 2020.
• (+)-N-methyllaurotetanine: An isoquinoline alkaloid with documented anti-inflammatory properties.
• (+)-Isoboldine: Another isoquinoline alkaloid with anti-inflammatory activity.
• β-carboline alkaloids (e.g., linderaggrine A): Linderaggrine A showed significant anti-inflammatory activity in superoxide anion generation with an IC50 value of 9.17 ± 0.40 µM as compared to positive control sorafenib (IC50 = 3.23 ± 0.42 µM).

3.3 Flavonoids

Flavonoids constitute a third major class of bioactive compounds. Identified flavonoids include astragaline, afzelin (kaempferol-3-O-rhamnoside), quercitrin, avicularin, and epicatechin. Anti-melanogenic antioxidants quercitrin and afzelin, among other constituents, have been identified from Lindera obtusiloba.

3.4 Lignans, Neolignans, and Butenolides (primarily in L. obtusiloba)

L. obtusiloba is a rich source of therapeutically beneficial antioxidative phytochemicals, such as flavonoids, butenolides, lignans, and neolignans. Active constituents identified from L. obtusiloba include anti-inflammatory antioxidants (+)-syringaresinol and linderin A, anti-atherosclerotic antioxidant (+)-episesamin, cytotoxic butenolide derivatives, anti-allergic koaburaside, and the antiplatelet-activity compound Secolincomolide A.

3.5 Essential Oils and Volatile Compounds

Plants from the Lindera genus are considered a rich source of essential oils and are often used in the production of aromatic cosmetic products such as soap and lubricants for their elegant fragrance.

3.6 Quality Control Markers

Only two active constituents, linderane and norisoboldine, have been designated as the chemical markers for quality control of L. aggregata in the China Pharmacopoeia 2020. However, it is widely acknowledged that the therapeutic efficacy of L. aggregata relies on the intricate interactions among numerous ingredients in combination, and relying on the determination of only two compounds may not adequately represent the overall clinical therapeutic effects.

4. Mechanisms of Action

4.1 Anti-Inflammatory Mechanisms

Key compounds including norisoboldine, isolinderalactone, methyllinderone, and linderin B have been shown to inhibit the production or expression of nitric oxide, inducible nitric oxide synthase (iNOS), tumor necrosis factor-α, and interleukin-6. Molecular docking of iNOS with isolinderalactone, methyllinderone, and linderin B showed that hydrogen bonds, π–π interactions, and hydrophobic interactions contributed to their iNOS inhibitory effects.

Regarding the alkaloid norisoboldine specifically, NOR can stably bind to the aryl hydrocarbon receptor (AhR), upregulate the nuclear translocation of AhR, and enhance the accumulation of the AhR-ARNT complex, AhR-mediated reporter gene activity, and CYP1A1 expression in RAW 264.7 cells, suggesting that NOR might be an agonist of AhR. Radix Linderae markedly inhibits the differentiation of osteoclasts in vitro, an effect likely associated with the inhibition of the NF-κB pathway.

4.2 Anti-Tumor Mechanisms

Isolinderalactone has been the focus of extensive mechanistic oncology research:

• In a human glioblastoma (GBM) xenograft mouse model, isolinderalactone decreased the expression of vascular endothelial growth factor (VEGF) mRNA, protein, and VEGF secretion in hypoxic GBM cells, with tumor suppression explained by inhibition of HIF-1α, HIF-2α, and VEGF promoter activity.
• Isolinderalactone inhibits the migration and invasion of lung cancer cells through its inhibition of MMP-2 and β-catenin expression.
• ILL treatment significantly suppressed proliferation and induced cell cycle G2/M arrest in colorectal cancer cells by inhibiting the expression of cyclin B, p-cdc2, and p-cdc25c and upregulating p21. In addition, ILL induced mitochondria-associated apoptosis through the upregulation of cleaved caspase-9 and -3 expression.
• ILL promotes bladder cancer cell apoptosis by regulating the BCL-2 family and CYCS, thereby inhibiting cell growth. Isolinderalactone induced the apoptosis of bladder cancer cells through the endogenous (mitochondrial) pathway.

4.3 Lipid-Lowering Mechanisms

Potential mechanisms for cholesterol-lowering effects of L. aggregata leaf aqueous extract (AqLA-L) include upregulation of cholesterol 7-alpha-hydroxylase (CYP7A1) and ATP-binding cassette transporter A1 (ABCA1), as well as downregulation of 3-Hydroxy-3-methylglutaryl CoA reductase (HMGCR).

4.4 Antioxidant Mechanisms

In animal studies, L. obtusiloba extract treatment significantly reduced vascular reactive oxygen species (ROS) formation and expression of NADPH oxidase subunits, including p22phox and p47phox. Mice exposed to chronic treatment exhibited reductions in plaque inflammation-related fluorescence signals and atherosclerotic lesions.

4.5 Anti-Platelet Mechanisms

Secolincomolide A from L. obtusiloba effectively inhibited collagen-induced platelet aggregation and serotonin secretion via decreased production of diacylglycerol, arachidonic acid, and cyclooxygenase-mediated metabolites such as thromboxane B2 (TXB2) and prostaglandin D2 (PGD2).

5. Scientific Evidence by Area of Use

5.1 Inflammation and Rheumatoid Arthritis

Evidence level: Pre-clinical (animal and in vitro); limited human data.

A study investigated the therapeutic potential of norisoboldine, the major isoquinoline alkaloid present in Radix Linderae, in collagen-II-induced arthritis (CIA) in mice. CIA was induced by immunization with chicken type II collagen. After boosting on day 21, mice were treated with norisoboldine (10, 20, 40 mg/kg) for twenty consecutive days. Norisoboldine treatment significantly alleviated the severity of the disease, based on reduced clinical scores and elevated body weights of model mice. This alkaloid dose-dependently reduced the infiltration of inflammatory cells, synovial hyperplasia, and protected joints from destruction.

A more recent study further characterized the mechanism: Rats were divided into five groups including normal control, RA model, NOR-treated groups at 15 mg/kg and 30 mg/kg, and a methotrexate-treated group. NOR's anti-arthritic effects were assessed by measuring clinical arthritis scores and inflammatory markers (RF, CRP, TNF-α, IL-6, IL-10), as well as oxidative stress markers and NF-κB/IKKβ and Nrf2/Keap1 pathways. NOR treatment significantly reduced arthritis severity.

Norisoboldine has been shown to ameliorate bone erosion in rats with adjuvant-induced arthritis at lower doses than required for the repression of systemic inflammation, exhibiting a direct anti-joint bone destruction effect.

At the cellular level, linderaggredin C, (+)-N-methyllaurotetanine, and (+)-isoboldine displayed significant inhibition of superoxide anion generation in human neutrophils with IC50 values of 7.45 ± 0.74, 8.36 ± 0.11, and 5.81 ± 0.59 μM, respectively. All arthritis evidence to date comes from animal and cell-line studies; no controlled human clinical trials of Lindera extracts or isolated compounds for rheumatoid arthritis have been published.

5.2 Anti-Tumor and Anti-Cancer Activity

Evidence level: Primarily in vitro (cell lines) and some animal models; no human clinical trials.

Isolinderalactone (ILL), a sesquiterpene isolated from the root extract of Lindera aggregata, has been reported to exhibit anti-proliferative and anti-metastatic activities in various cancer cell lines. The mechanisms associated with its antitumor effects on colorectal cancer cells remain under investigation.

Studies have demonstrated activity across multiple cancer types:

• Glioblastoma: A prior report showed that isolinderalactone enhances GBM apoptosis in vitro; in a human GBM xenograft mouse model, isolinderalactone significantly reduced tumor growth and vessels.
• Lung cancer: In a cell line study, 1–10 µM ILL was applied in the culturing of the A549 lung cancer cell line to investigate the effects on invasion and migration; ILL inhibited the invasion and migration of A549 cancer cells and exhibited a dose-response association.
• Ovarian cancer: ILL induces the death of human ovarian cancer cells by upregulating mitochondrial superoxide and inactivating the STAT3-mediated pathway.
• Colorectal cancer: ILL treatment significantly suppressed proliferation and induced cell cycle G2/M arrest in colorectal cancer (CRC) cells by inhibiting the expression of cyclin B, p-cdc2, and p-cdc25c and upregulating p21, and induced mitochondria-associated apoptosis through upregulation of cleaved caspase-9 and -3.
• Bladder cancer: ILL reduces the antiapoptotic X-linked inhibitor of apoptosis protein and BCL-2 proteins, thereby increasing caspase-3 lysis and apoptosis, and retarding tumor growth in human glioblastomas in vitro and in vivo.

While the pharmacological effects of L. aggregata have been confirmed in multiple studies, most studies only use simple in vitro cell lines or animal disease models to evaluate their pharmacological activities. There are no published human clinical trials of Lindera constituents as anti-cancer interventions.

5.3 Urinary System: Overactive Bladder and Urinary Incontinence

Evidence level: One phase-2 RCT for a combination product; traditional use for thousands of years.

A phase-2, randomized, double-blind, placebo-controlled trial assessed the efficacy of Urox®, a proprietary combination product containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem, and Lindera aggregata root, in the treatment of symptoms of overactive bladder (OAB) and urinary incontinence (UI). At week 8, urinary day frequency was significantly lower (OR 0.01; 95% CI 0.01 to 0.02). Because this trial tested a three-herb combination product, the individual contribution of Lindera aggregata root to these outcomes cannot be isolated from the published data.

5.4 Cardiovascular and Atherosclerosis

Evidence level: Animal and in vitro studies only; no human clinical trials.

Lindera obtusiloba extract (LOE), a traditional herbal medicine used to enhance blood circulation and reduce inflammation, induced NO-mediated endothelium-dependent relaxation and reduced the formation of reactive oxygen species. The study investigated whether LOE improves endothelial dysfunction and reduces plaque inflammation and progression by inhibiting ROS generation in a mouse model of atherosclerosis, using apolipoprotein E-deficient (apoE−/−) mice fed a Western diet, randomized into groups receiving vehicle, LOE (100 mg/kg/day), or losartan (30 mg/kg/day) by gavage until 28 weeks. LOE treatment improved endothelial dysfunction and reduced plaque inflammation as well as lesion areas by reducing vascular NADPH oxidase-induced ROS generation in this mouse model.

Regarding isolinderalactone and atherosclerosis: ApoE−/− mice fed a high-fat/cholesterol diet for 8 weeks were administered different doses of ILL (5 and 10 mg/kg by intraperitoneal injection every other day); ILL significantly reduced the size and foam of atherosclerotic lesions in HFD-fed ApoE−/− mice.

Secolincomolide A isolated from L. obtusiloba exhibited strong inhibitory effects on collagen-induced platelet aggregation and activation, with antiplatelet action occurring via inhibiting thrombotic metabolite formation and GPVI-mediated signaling pathway; it may be a new therapeutic candidate for the prevention/treatment of atherosclerosis and vascular restenosis. All cardiovascular evidence remains at the pre-clinical level.

5.5 Lipid Metabolism and Hyperlipidemia

Evidence level: Animal studies; no human clinical trials.

Aqueous extract of L. aggregata leaf (AqLA-L) at doses of 0.3, 0.6, and 1.2 g/kg remarkably lowered serum total cholesterol (TC), triglycerides (TG), LDL, non-HDL cholesterol, ALT, and glucose, and increased serum HDL and APOA-I levels in hyperlipidemic mice. These results revealed that AqLA-L treatment regulated the disorders of serum lipid and liver function. Traditionally, the leaves of L. aggregata have been used as functional teas or dietary supplements to prevent and treat hyperlipidemia, offering antioxidant, hepatoprotective, cardiovascular protective, and lipid-lowering effects.

5.6 Neuroprotection and Cognitive Function

Evidence level: Animal and in vitro studies only.

In vivo behavioral experiments (Y-maze and Morris water maze test) confirmed that L. obtusiloba methanol extract alleviated cognitive impairments induced by scopolamine and decreased iNOS expression in the hippocampus. These compounds were reported for their potential pharmacological effects, including antioxidant, antiatherosclerotic, antihistamine, antiplatelet, anti-inflammatory, and neuroprotective effects.

5.7 Respiratory and Allergic Inflammation

Evidence level: Animal model study only.

A study investigating L. obtusiloba leaves (LOL) in an ovalbumin-challenged allergic asthma mouse model found that female BALB/c mice sensitized with OVA and administered 50 and 100 mg/kg of LOL by oral gavage 1 hour before the challenge showed that LOL treatment effectively decreased airway hyper-responsiveness and inhibited inflammatory cell recruitment, Th2 cytokines, and mucin 5AC (MUC5AC) in bronchoalveolar lavage fluid.

5.8 Renal Protection and Diabetic Nephropathy

Evidence level: Animal studies only.

Animal research demonstrates that Lindera slows the progression of diabetic nephropathy and could therefore be used as a preventative approach to protect renal function from deterioration. Use of Lindera can result in improved renal function, as evaluated by creatinine clearance and serum creatinine.

6. Body Systems Associated with Lindera

Ongoing pharmacological studies have demonstrated the potential of L. aggregata in various areas, such as anti-cancer, anti-inflammatory, anti-arthritis, anti-bacterial, anti-oxidation, anti-diabetic nephropathy, hepatoprotective, and lipid-lowering effects.

Based on reviewed evidence, the body systems most associated with Lindera include:

• Genitourinary System: Traditional use for urinary frequency, incontinence, bladder cold, hernia, dysmenorrhea; some clinical combination-product data.
• Musculoskeletal System: Anti-inflammatory and anti-arthritic use in TCM; pre-clinical evidence for rheumatoid arthritis and bone erosion.
• Gastrointestinal System: Roots of L. aggregata could treat diseases of the gastrointestinal tract, metabolism, inflammation, and urinary system.
• Cardiovascular System: Pre-clinical evidence for anti-platelet, anti-atherosclerotic, and endothelial protective effects.
• Oncology (pre-clinical): Multiple in vitro and animal models demonstrating ILL activity across cancer types.
• Hepatic System: Liver-protective activity attributed to germacrane and eudesmane sesquiterpenes, and leaf extracts for lipid control.
• Renal System: Traditional indication for kidney warming; animal evidence for diabetic nephropathy protection.
• Central Nervous System: Animal evidence for anti-amnesic and neuroprotective effects of L. obtusiloba.
• Respiratory System: Animal evidence for anti-asthmatic and anti-allergic effects of L. obtusiloba.

7. Dosage Forms and Reported Dosages

The dosage of Wuyao (dried root) in traditional practice should be controlled between 5–10 g. It can be made into decoctions, pills, or powdered forms for external application.

Specific dosages reported in experimental studies include:

• Norisoboldine (collagen-induced arthritis, mouse model): Mice were treated with norisoboldine at 10, 20, and 40 mg/kg for twenty consecutive days.
• Norisoboldine (rheumatoid arthritis, rat model): NOR-treated groups received doses of 15 mg/kg and 30 mg/kg.
• Isolinderalactone (atherosclerosis, mouse model): Different doses of ILL (5 and 10 mg/kg, by intraperitoneal injection every other day) were assessed in ApoE−/− mice fed a high-fat/cholesterol diet.
• L. obtusiloba extract (atherosclerosis, mouse model): LOE was administered at 100 mg/kg/day by gavage until 28 weeks of age.
• L. obtusiloba leaf extract (asthma, mouse model): Mice were administered 50 and 100 mg/kg of LOL by oral gavage 1 hour before the OVA challenge.
• L. aggregata leaf aqueous extract (hyperlipidemia, mouse model): AqLA-L was tested at 0.3, 0.6, and 1.2 g/kg in hyperlipidemic mice.
• Isolinderalactone (lung cancer cell line): 1–10 µM ILL was applied in the culturing of A549 lung cancer cells.

The maximum non-effective dose of L. aggregata has been reported as 5.0 g/kg of body weight in animal toxicity studies.

8. Safety Considerations and Interactions

8.1 General Toxicology

Wuyao is classified as non-toxic (无毒) in both classical sources and the modern Chinese Pharmacopoeia. No toxic components have been identified at standard dosages, and no significant adverse effects have been reported in standard clinical use.

Administration of L. aggregata to rats and mice did not cause acute poisoning, nor did it cause mutations in genes, chromosomes, or cells; however, high doses caused relatively non-pathological enlargement of the animal liver with no significant effect on various indicators of liver function and histopathological observation.

8.2 Traditional Contraindications

Classical TCM texts and modern pharmacopoeial guidance identify specific contraindications:

• Wuyao should not be used or requires extra caution in patients with Qi deficiency patterns. It is a Qi-moving herb that disperses and dissipates, and in people with underlying Qi deficiency, it can further deplete Qi and worsen fatigue, weakness, and other deficiency symptoms.
• Patients with Qi deficiency or internal heat should not take it. Pregnant women and individuals with weakened constitutions should avoid taking it.

8.3 Evidence Strength and Research Limitations

A large number of in vivo and in vitro studies have shown that L. aggregata has a plethora of pharmacological effects such as anti-cancer, anti-arthritis, anti-bacterial, anti-oxidation, anti-diabetic nephropathy, hepatoprotective, and lipid-lowering effects. However, most studies only use simple in vitro cell lines or animal disease models to evaluate their pharmacological activities. Additional studies are needed to confirm the relationship between the traditional effects of L. aggregata and modern pharmacological research. Future investigations on L. aggregata should focus on modern pharmacological research to confirm or support its traditional application.

In summary: the body of evidence for Lindera spp. is predominantly pre-clinical — comprising in vitro cell-based assays and animal disease models. The one published human clinical trial involves a proprietary three-herb combination product (Urox®) for overactive bladder, making it impossible to attribute outcomes to Lindera alone. There are no published controlled clinical trials of isolated Lindera extracts or compounds — such as norisoboldine or isolinderalactone — in human subjects for any indication. The traditional use record in TCM is extensive and multi-century, but constitutes a separate category of evidence from prospective controlled research.

References

• Therapeutic Potential of Lindera obtusiloba: Focus on Antioxidative and Pharmacological Properties — PMC (Plants, 2020)
• A review on the chemical constituents and pharmacological efficacies of Lindera aggregata (Sims) Kosterm — PubMed / Frontiers in Nutrition (2023)
• Frontiers in Nutrition: A review on the chemical constituents and pharmacological efficacies of Lindera aggregata (Sims) Kosterm (2022)
• Traditional uses, phytochemistry, pharmacology, processing methods and quality control of Lindera aggregata (Sims) Kosterm: A critical review — PubMed (2023)
• Traditional uses, phytochemistry, pharmacology, processing methods and quality control of Lindera aggregata: A critical review — ScienceDirect / Journal of Ethnopharmacology (2023)
• Lindera aggregata (Sims) Kosterm: a systematic review of its traditional applications, phytochemical and pharmacological properties, and quality control — Medicinal Plant Biology (2023)
• Anti-inflammatory principles from Lindera aggregata — PubMed (2020)
• Characterization and quantification of the phytochemical constituents and anti-inflammatory properties of Lindera aggregata — PMC / RSC Advances (2024)
• Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice — PubMed (2010)
• Norisoboldine, an Anti-Arthritis Alkaloid Isolated from Radix Linderae, Attenuates Osteoclast Differentiation and Inflammatory Bone Erosion in an Aryl Hydrocarbon Receptor-Dependent Manner — PMC / International Journal of Biological Sciences (2015)
• Norisoboldine Reduces Arthritis Severity by Attenuating Inflammation, Oxidative Stress, and Extracellular Matrix Degradation in a Rat Model of Rheumatoid Arthritis — PMC (2024)
• A Standardized Lindera obtusiloba Extract Improves Endothelial Dysfunction and Attenuates Plaque Development in Hyperlipidemic ApoE-Knockout Mice — PMC / Plants (2021)
• Inhibition of Collagen-Induced Platelet Aggregation by Secolincomolide A from Lindera obtusiloba Blume — PMC (2017)
• Mitigating Effect of Lindera obtusiloba Blume Extract on Neuroinflammation in Microglial Cells and Scopolamine-Induced Amnesia in Mice — PMC (2021)
• Lindera obtusiloba Attenuates Oxidative Stress and Airway Inflammation in a Murine Model of Ovalbumin-Challenged Asthma — PMC (2020)
• Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models — ScienceDirect / Cancer Letters (2020)
• Anti-metastatic effects of isolinderalactone via the inhibition of MMP-2 and upregulation of NM23-H1 expression in human lung cancer A549 cells — PMC / Oncology Letters (2018)
• Isolinderalactone Induces Apoptosis, Autophagy, Cell Cycle Arrest and MAPK Activation through ROS-Mediated Signaling in Colorectal Cancer Cell Lines — PMC / International Journal of Molecular Sciences (2023)
• Lindera — Trees and Shrubs Online
• The Herb Society of America Essential Facts for Spicebush Lindera benzoin
• Spicebush: Research Notes — Medicinal Forest Garden Trust
• Multi-omics profiling reveals organ-specific anti-inflammatory metabolites and biosynthetic regulation in Lindera aggregata taproot-bark — ScienceDirect (2025)